ALT - CIK 0001326190
Altimmune, Inc. trades as ALT. In its fiscal 2025 annual report the company posted revenue of $41.00K, up 105.0% from the prior year and net income of -$88.09M. This page tracks Altimmune, Inc. through 997 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Altimmune, Inc.'s revenue declined from $3.24M to $41.00K, a compound annual decline rate of 38.5%. Net profit margin compressed from -342.6% to -214861.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Employee stock plan | S-8 | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| SCHEDULE 13G | - | 2026-05-12 |
| Insider trade | 4 | 2026-05-01 |
| Insider trade | 4 | 2026-05-01 |
| Insider trade | 4 | 2026-05-01 |
The largest companies sharing Altimmune, Inc.'s SEC industry classification (pharmaceutical preparations).
Altimmune, Inc. reported revenue of $41.00K for fiscal year 2025, an increase of 105.0% year over year.
In its latest fiscal year Altimmune, Inc. reported a net loss of $88.09M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.